Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immunocore Holdings plc IMCR

Healthcare Biotechnology
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and... see more

Recent & Breaking News (NDAQ:IMCR)

Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV

GlobeNewswire July 11, 2022

Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress(TM)

GlobeNewswire June 25, 2022

Immunocore Appoints Siddharth Kaul to its Board of Directors

GlobeNewswire June 9, 2022

The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma

GlobeNewswire June 8, 2022

Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire June 6, 2022

Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi's product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma

GlobeNewswire June 3, 2022

Immunocore to present at upcoming investor conferences

GlobeNewswire June 1, 2022

Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire May 26, 2022

Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand

PR Newswire May 23, 2022

Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire May 11, 2022

Immunocore to present at the 21st Annual Needham Healthcare Conference

GlobeNewswire April 7, 2022

European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma

GlobeNewswire April 4, 2022

Immunocore to present at Oppenheimer's 32nd Annual Healthcare Conference

GlobeNewswire March 9, 2022

Immunocore Reports Full Year 2021 Financial Results and Provides Business Update

GlobeNewswire March 3, 2022

Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma

GlobeNewswire February 25, 2022

Immunocore to present at the SVB Leerink Global Healthcare Conference

GlobeNewswire February 11, 2022

Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma

GlobeNewswire January 26, 2022

Immunocore to present at the 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 6, 2022

Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4

GlobeNewswire December 6, 2021

Immunocore to present at the Jefferies London Healthcare Conference

GlobeNewswire November 11, 2021